SPONSORSHIP PROSPECTUS 5Th Annual Cell & Gene Therapy Investor Day April 27, 2017 Boston, MA

SPONSORSHIP PROSPECTUS 5th Annual Cell & Gene Therapy Investor Day April 27, 2017 Boston, MA

www.arminvestorday.com Cell & Gene Therapy Investor Day Event Overview This one-day, invitation-only meeting provides institutional, strategic and venture investors with unique insight into the investment hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurode- generative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the indus- try, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.

Past Attending Organizations (partial list) 4BIO Capital Partners Casdin Capital HS Management Partners PCT, A Caladrius Company 4D Molecular Therapeutics Cato BioVentures Informa Piper Jaffray 722 Investments Cedar Lane Fund Inovio Pharmaceuticals Plaza Capital Partners Abeona Therapeutics Celgene Cellular Therapeutics Integral Capital Partners Plexus Capital Management Able Capital Cellectis Intellia Therapeutics Pluristem Therapeutics ABN Newswire Celyad Investor Growth Capital Pollack Asset Management Accelerated Biosciences CES Investments Ironridge Global Partners Pond Capital Adverum Biotechnologies Cesca Therapeutics Janssen R&D Popular Science AFM Investment Fund Chardan Capital Markets JDRF Princeton Capital AGTC Columbia Technology Ventures JETRO New York ProActive Capital Aisling Capital Columbus Circle Investors Jefferies Promethera Biosciences Ajinomoto North America Cord Blood Registry JMP Securities Regenerate Capital Akre Capital Management Cornerstone Capital JonesTrading Institutional Regeneus AlephPoint Capital Cova Capital Partners Juventas Therapeutics REGENXBIO Alere Financial Partners Crown Point Group Kahn Brothers Group ReNeuron Ally Bridge Group Cryoport Kareg / Katalyst Securities Ridgeback Capital Almorli Capital CTI Clinical Trial & Consulting Kawasaki Heavy Industries Rockmore Capital Alpha Bronze Cubist Pharmaceuticals Kingdom Capital Root Capital Management Amach Capital Partners Cynata Therapeutics Knoll Capital Management ROTH Capital Partners Amarantus Dabar Investment Associates Ladenburg Thalmann & Co. RTW Investments Amiel Capital Group Deca Ventures Laidlaw and Co. Sangamo BioSciences Apache Capital Management Deerfield Management Lake Street Capital Markets Sanofi Apple Tree Partners Delwar Capital Management Lancet Capital SBS Securities Aquilo Partners Discover Fund Lazard Capital Markets Scientific American ARCH Venture Partners DLD Asset Management Lexington Capital Scottish Development Intl Argos Therapeutics Domain Associates Liberte Global Investors Group Seaview Securities Ascendiant Capital Markets DTB Capital Management Lincoln Park Capital Seeking Alpha Ascent Capital Management Deutsche Asset Management Lion Biotechnologies Shire Asclepia Capital Eagle Asset Management Loeb Partners Sichel Medical Ventures Asterias Biotherapeutics Edison Investment Research Lonza SilverBirch Capital Athersys Ellington Healthcare Partners M3 Capital Partners Sofia Investment Fund Atlantic Capital Group EMD Serono MaxCyte Sophrosyne Capital Atlas Partners Equities First Holdings Maxim Group Stanphyl Capital GP Audentes Therapeutics Fate Therapeutics Medical Device Daily Stonebridge Holdings Auriga Capital Management Felman Family Office Medisun Holdings Symmetry Capital Avita Medical Ferghana Partners Medpace Syzygy Therapeutics AXA Advisors Fibrocell Science Medtech Insight Teleos Capital Bain Capital FIC Capital Merck Temasek Bioscience Partners Barclays First Eagle Investment Merrill Lynch The Charlton Group Basu Capital Fletcher Spaght Ventures Mesoblast The Life Sciences Report BCC Research Fountain Healthcare Partners MiMedx Group The Pink Sheet Bedford Global F-Prime Capital Mizuho Corporate Bank The Stem Cell Stock Index Bellicum Pharmaceuticals Gagnon Securities MLV & Co. TheStreet Bell Potter Securities Galaxiom/Noveltek Capital Monarch Capital Group TiGenix Belmont Capital GAP Ventures Montaur Capital Partners Titan Securities Benitec Biopharma GC Finance Morgan Stanley TrakCel Bifrost Capital GE Healthcare Life Sciences Mountain Brook Capital Triathlon Medical Ventures BioCentury Publications Gemstone Biotherapeutics MPM Capital Trinity Financing Investments BioDecade Genetic Engineering News Murdock Capital Partners TriPoint Global Equities Biogen GenSight Biologics NEA Trout Group BioMarin Pharmaceuticals Gilford Securities Needham & Company Tsuri Limited BioPharm Insight Global Thematic Partners Northlea Partners TxCell Biotechnology Law Report Goodrich Capital Novartis uniQure Black Diamond Advisors Gotham Investors Numoda Capital Innovations VenBio Bloomberg News Great Point Partners Oppenheimer & Co. Venrock bluebird bio GXZ investments Opus Point Partners Versant Ventures Bone Therapeutics Halcyon Cabot Partners Orbimed ViaCyte BrainStorm Cell Therapeutics HealthPro BioVentures Osiris Therapeutics Visium Funds Brio Capital Hercules Growth Capital Oxford BioMedica Voyager Therapeutics Broadview Ventures HighCape Partners Pansend Wall Street Journal Capricor Therapeutics Histogenics Passport Capital Wolf Capital Management Carthage Capital Management Horizon Technology Finance Park Ave Capital World Tech Ventures

www.arminvestorday.com 2017 Sponsorship Opportunity Overview

Cell & Gene Therapy Investor Day Benefits Lead Supporting Gold Silver Co-Host Co-Host Sponsor Sponsor

Full-Day Registration Passes* Therapeutic & Investor Panels Company Presentations (Both Public & Private) 8 6 4 2 All Meals, Breaks & Evening Reception *Passes May Be Used for Company Reps or Clients half page co. co. Event Program Advertisement full page ad ad description description

Logo, Link & Co. Description on Event Website x x x x

Logo Recognition on All Event Marketing Materials Invitations to Investors, Speakers & Presenting Companies x x x x Event Website, Online Registration Forms & Press Releases Signage & Looping PPTs Throughout Conference

Ability to Display Materials at Conference x x x 6ft. tabletop display only (no booths)

Planning / Post Event Input: Active Role in Determining Speaker/Panel Topics Ability to Suggest & Invite Presenting Companies* x x Receive Complete List of Attendees Post Event *All company presenters must be approved by ARM

Lead Co-Host Speaking Roles: Ability to Moderate Two Featured Panel Discussions/Sessions x Ability to Have Analyst Introduce and Moderate Company Presentations (exact # depends on level and # of co-hosts)

Supporting Co-Host Speaking Roles: Ability to Moderate One Featured Panel Discussion/Session x Ability to Have Analyst Introduce and Moderate Company Presentations (exact # depends on level and # of co-hosts)

• Exclusive Lanyard Sponsor • Exclusive Sponsor for Pre-Event Private Dinner Choose 1 • Exclusive Breakfast & Lunch Sponsor • Upgrade to Half-Page Program Advertisement

$40,000 $20,000 $10,000 $5,000

For more information about sponsorship opportunities and additional 2017 Cell & Gene Therapy Investor Day de- tails, please contact Laura Parsons at [email protected]. We look forward to working with you.